Tasly released its 2026 interim report. Net profit attributable to the parent in the first half reached 893 million yuan, up 15.2% year on year. Operating revenue was 4.201 billion yuan, down 2.03% year on year. Net profit attributable to the parent excluding non-recurring items was 870 million yuan, up 36% year on year. Net operating cash flow was 1.17 billion yuan, up 48.2% year on year. Second-quarter net profit attributable to the parent was 522 million yuan, up 13.5% year on year. The company said it will continue to strengthen research and development and market promotion to cope with industry competition and market changes.
Tasly Pharmaceutical Group Co LtdNet profit attributable to parent up 15.2% YoY, with core profit up 36% and operating cash flow up 48.2%.
